dc.contributor.authors |
Karacaer, Cengiz; Yurtsever, Zubeyir; Dheir, Hamad; Yaylaci, Selcuk; Varim, Ceyhun; Nalbant, Ahmet; Demirci, Taner; Kaya, Tezcan |
|
dc.date.accessioned |
2022-12-20T13:24:45Z |
|
dc.date.available |
2022-12-20T13:24:45Z |
|
dc.date.issued |
2022 |
|
dc.identifier.issn |
0393-6384 |
|
dc.identifier.uri |
http://dx.doi.org/10.19193/0393-6384_2022_4_362 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/98966 |
|
dc.description |
Bu yayının lisans anlaşması koşulları tam metin açık erişimine izin vermemektedir. |
|
dc.description.abstract |
Objective: The study aims to determine whether ACEI/ARB use associated with an increased probability of viral infection and investigate whether there are differences in disease severity and mortality between ACEI/ARB users and non-ACEI/ARB users. Material and methods: In this retrospective study, 330 patients with severe acute respiratory syndrome coronavirus 2 disease were divided into two groups: patients using ACEI/ARB Blocker and patients not using it. Baseline features and prognoses were compared for the two groups. Results: The rate of intensive care hospitalization in the group using ACE/ARB was significantly (p<0.05) higher than the group not using ACEI/ARB on the day of hospitalization in the intensive care unit. The degree of clinical classification in the group using ACEI/ARB was significantly (p<0.05) higher than the group not using ACE/ARB. The mortality rate in the group using ACE/ARB was significantly (p<0.05) higher than the group not using ACEI/ARB. Conclusion: Although it has been determined that the use of antihypertensive ACEI/ARB in COVID 19 patients is associated with mortality and survival, it has been concluded that the continuation of ACEI/ARB use would be more appropriate for the continuation of antihypertensive treatment. |
|
dc.language |
English |
|
dc.language.iso |
eng |
|
dc.relation.isversionof |
10.19193/0393-6384_2022_4_362 |
|
dc.subject |
General & Internal Medicine |
|
dc.subject |
COVID-19 |
|
dc.subject |
angiotensin-converting enzyme inhibitor |
|
dc.subject |
angiotensin II receptor blocker |
|
dc.subject |
hypertension |
|
dc.subject |
mortality |
|
dc.title |
DOES ANGIOTENSIN II RECEPTOR BLOCKERS/ANGIOTENSIN CONVERTING ENZYME INHIBITORS INCREASE THE RISK OF COVID-19 INFECTED PATIENTS? |
|
dc.contributor.authorID |
Kaya, Tezcan/0000-0003-0483-2333 |
|
dc.identifier.volume |
38 |
|
dc.identifier.startpage |
2375 |
|
dc.identifier.endpage |
2379 |
|
dc.relation.journal |
ACTA MEDICA MEDITERRANEA |
|
dc.identifier.issue |
4 |
|
dc.identifier.doi |
10.19193/0393-6384_2022_4_362 |
|
dc.identifier.eissn |
2283-9720 |
|
dc.contributor.author |
Karacaer, Cengiz |
|
dc.contributor.author |
Yurtsever, Zubeyir |
|
dc.contributor.author |
Dheir, Hamad |
|
dc.contributor.author |
Yaylaci, Selcuk |
|
dc.contributor.author |
Varim, Ceyhun |
|
dc.contributor.author |
Nalbant, Ahmet |
|
dc.contributor.author |
Demirci, Taner |
|
dc.contributor.author |
Kaya, Tezcan |
|
dc.relation.publicationcategory |
Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı |
|